In DepthBiomedicine

Combo of two HIV vaccines fails its big test

See allHide authors and affiliations

Science  07 Feb 2020:
Vol. 367, Issue 6478, pp. 611-612
DOI: 10.1126/science.367.6478.611

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

The failure-ridden search for a vaccine that can stop the AIDS virus has delivered yet another frustrating defeat. The HIV vaccine that had moved furthest along in human testing does not work, and the $104 million trial in South Africa evaluating it has been stopped early. The efficacy study, which began in October 2016, is known as HVTN 702. It enrolled 5407 sexually active, HIV-uninfected men and women between 18 and 35 years of age at 14 sites across the country. Researchers randomly assigned half of the participants to receive a pair of HIV vaccines used in a one-two punch called a prime boost, whereas the other half received placebo shots. The trial was supposed to last until July 2022. But on 23 January, an independent monitoring board that takes scheduled sneak peaks at the data to evaluate safety and efficacy informed the leaders of the study that it was "futile" to continue.

View Full Text

Stay Connected to Science